The clinical position of ramucirumab-containing regimens for advanced gastric cancer: a review of clinical trial data

被引：4

作者：

Iwasa, Satoru ^{[1
]}

Bando, Hideaki ^{[2
]}

Piao, Yongzhe ^{[3
]}

Yoshizawa, Kenichi ^{[4
]}

Yamaguchi, Kensei ^{[5
,6
]}

机构：

[1] Natl Canc Ctr, Gastrointestinal Med Oncol Div, Tokyo 1040045, Japan

[2] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba 2770882, Japan

[3] Eli Lilly Japan KK, Med Dev Unit Japan, Kobe, Hyogo 6510086, Japan

[4] Eli Lilly Japan KK, Safety Sci, Kobe, Hyogo 6510086, Japan

[5] Japanese Fdn Canc Res, Dept Gastroenterol Chemotherapy, Canc Inst Hosp, Tokyo 1350063, Japan

[6] Saitama Canc Ctr, Dept Gastroenterol, Saitama 3620806, Japan

来源：

FUTURE ONCOLOGY | 2022年 / 18卷 / 21期

关键词：

gastric cancer; gastroesophageal cancer; ramucirumab; VEGFR2; MULTICENTER PHASE-II; PLACEBO PLUS PACLITAXEL; GASTROESOPHAGEAL JUNCTION; ELDERLY-PATIENTS; DOUBLE-BLIND; 1ST-LINE CHEMOTHERAPY; COMBINATION THERAPY; DISEASE PROGRESSION; 2ND-LINE TREATMENT; JAPANESE PATIENTS;

D O I：

10.2217/fon-2022-0281

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Despite the availability of multiple treatment options, the prognosis for advanced gastric cancer (AGC) remains poor and more effective treatment options are needed. Ramucirumab is an established and recommended second-line treatment for AGC. In recently completed and ongoing clinical trials, ramucirumab has been investigated in combination with new therapeutics and in new clinical settings to address the unmet treatment needs of AGC. In this review, the findings of recent clinical trials are discussed. The aims of this review are to present the current picture of ramucirumab-containing regimens in AGC and offer practical guidance on the clinical position and target populations of ramucirumab-containing regimens in light of emerging therapeutic developments.

引用

页码：2709 / 2722

页数：14

共 52 条

[1]

Al-Batran SE, 2020, J CLIN ONCOL, V38

[2] A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer [J].

Bando, Hideaki ;

Shimodaira, Hideki ;

Fujitani, Kazumasa ;

Takashima, Atsuo ;

Yamaguchi, Kensei ;

Nakayama, Norisuke ;

Takahashi, Takehiro ;

Oki, Eiji ;

Azuma, Mizutomo ;

Nishina, Tomohiro ;

Hironaka, Shuichi ;

Komatsu, Yoshito ;

Shitara, Kohei .

EUROPEAN JOURNAL OF CANCER, 2018, 91 :86-91

[3] Efficacy and safety of S-1 and oxaliplatin combination therapy in elderly patients with advanced gastric cancer [J].

Bando, Hideaki ;

Yamada, Yasuhide ;

Tanabe, Satoshi ;

Nishikawa, Kazuhiro ;

Gotoh, Masahiro ;

Sugimoto, Naotoshi ;

Nishina, Tomohiro ;

Amagai, Kenji ;

Chin, Keisho ;

Niwa, Yasumasa ;

Tsuji, Akihito ;

Imamura, Hiroshi ;

Tsuda, Masahiro ;

Yasui, Hirofumi ;

Fujii, Hirofumi ;

Yamaguchi, Kensei ;

Yasui, Hisateru ;

Hironaka, Shuichi ;

Shimada, Ken ;

Miwa, Hiroto ;

Hamada, Chikuma ;

Hyodo, Ichinosuke .

GASTRIC CANCER, 2016, 19 (03) :919-926

[4] Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ) [J].

Bang, Yung-Jue ;

Golan, Talia ;

Dahan, Laetitia ;

Fu, Siqing ;

Moreno, Victor ;

Park, Keunchil ;

Geva, Ravit ;

De Braud, Filippo ;

Wainberg, Zev A. ;

Reck, Martin ;

Goff, Laura ;

Laing, Naomi ;

Mi, Gu ;

Oliveira, Joana M. ;

Wasserstrom, Heather ;

Lin, Chia-Chi .

EUROPEAN JOURNAL OF CANCER, 2020, 137 :272-284

[5]

Bristol Myers Squibb, 2021, Bristol-MyersSquibb Positive Opinion Recommendation

[6] Ramucirumab in Combination with Pembrolizumab in Treatment-Naive Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial [J].

Chau, Ian ;

Penel, Nicolas ;

Soriano, Andres O. ;

Arkenau, Hendrik-Tobias ;

Cultrera, Jennifer ;

Santana-Davila, Rafael ;

Calvo, Emiliano ;

Le Tourneau, Christophe ;

Zender, Lars ;

Bendell, Johanna C. ;

Mi, Gu ;

Gao, Ling ;

McNeely, Samuel Clark ;

Oliveira, Joana M. ;

Ferry, David ;

Herbst, Roy S. ;

Fuchs, Charles S. .

CANCERS, 2020, 12 (10) :1-16

[7] Ramucirumab (R) plus pembrolizumab (P) in treatment naive and previously treated advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A multi-disease phase I study. [J].

Chau, Ian ;

Bendell, Johanna C. ;

Calvo, Emiliano ;

-Davila, Rafael Santana ;

Arkenau, Hendrik-Tobias ;

Mi, Gu ;

Jin, Jin ;

Rege, Jessicca ;

Ferry, David ;

Herbst, Roy S. ;

Fuchs, Charles S. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

[8] A post-marketing observational study of ramucirumab in patients with gastric cancer in Japan [J].

Chen, Yucherng ;

Katayose, Taeko ;

Nagaoka, Soshi ;

Piao, Yongzhe ;

Yamaguchi, Kensei ;

Asou, Hiroya .

GASTRIC CANCER, 2021, 24 (06) :1320-1329

[9] Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study [J].

Di Bartolomeo, Maria ;

Niger, Monica ;

Tirino, Giuseppe ;

Petrillo, Angelica ;

Berenato, Rosa ;

Laterza, Maria Maddalena ;

Pietrantonio, Filippo ;

Morano, Federica ;

Antista, Maria ;

Lonardi, Sara ;

Fornaro, Lorenzo ;

Tamberi, Stefano ;

Giommoni, Elisa ;

Zaniboni, Alberto ;

Rimassa, Lorenza ;

Tomasello, Gianluca ;

Sava, Teodoro ;

Spada, Massimiliano ;

Latiano, Tiziana ;

Bittoni, Alessandro ;

Bertolini, Alessandro ;

Proserpio, Ilaria ;

Bencardino, Katia Bruna ;

Graziano, Francesco ;

Beretta, Giordano ;

Galdy, Salvatore ;

Ventriglia, Jole ;

Scagnoli, Simone ;

Spallanzani, Andrea ;

Longarini, Raffaella ;

De Vita, Ferdinando .

TARGETED ONCOLOGY, 2018, 13 (02) :227-234

[10] Gastric carcinogenesis: a comprehensive review of the angiogenic pathways [J].

Forma, Alicja ;

Tyczynska, Magdalena ;

Kedzierawski, Pawel ;

Gietka, Klaudyna ;

Sitarz, Monika .

CLINICAL JOURNAL OF GASTROENTEROLOGY, 2021, 14 (01) :14-25

← 1 2 3 4 5 6 →